SynapCyte is a regenerative bio-therapeutic company focused on research, development, regulatory approval and commercialization of therapies for the treatment of Alzheimer’s and Parkinson’s diseases.

SynapCyte’s patented technologies are designed to treat Alzheimer’s and Parkinson’s disease by stimulating in the patient’s brain the production and proliferation of the endogenous (pre-existing) human stem cells (HNSC’s), thus regenerating neural (brain) cells lost in patient’s suffering from these neurodegenerative diseases.

Why Alzheimer's Disease?

With an aging baby boomer population, this disease is reaching epidemic proportions within the US, afflicting 5.5 million Americans in 2018, and this number is projected to double over the next 10 years.

Why Parkinson's Disease?

Parkinson’s is a debilitating neurodegenerative disease affecting more than 1 million Americans with the addition of 60,000 new cases annually.

Meet Our Team

Find out more about SynapCyte and its’ contributors.

Latest News

Meet the first 5 startups in UCF's new $4M Lake Nona Life Sciences Incubator

The University of Central Florida’s new 10,000-square-foot Lake Nona Life Sciences Incubator, which opened May 10 on the second floor…

March 1, SynapCyte moves into new offices and wet lab

SynapCyte LLC announces it’s move to the University of Central Florida’s (UCF’s) new Life Sciences Incubator located in the Guidewell…

SynapCyte receives guidance from FDA to begin preclinical trials

SynapCyte receives guidance from the Food and Drug Administration to begin preclinical trials in 2018 on its KS-217 patent for…